anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Interstitial fibrosis and tubular atrophy (IFTA), previously known as chronic allograft nephropathy (CAN), is diagnosed by pathologic changes involving all parts of the renal parenchyma and is one of the factors impacting graft survival and outcome. Currently, there is no standard to predict allograft fibrosis status at the time of procurement. Noninvasive biomarkers are necessary to monitor allograft status and to predict long-term outcomes.

The investigators aim to conduct a multicenter prospective study to identify urinary exosomal biomarkers that represent the extent of graft fibrosis from deceased donor kidney transplantation. Urinary samples will be collected from deceased kidney donors at the time of procurement and zero-day kidney graft biopsy will be performed at the time of transplant. The zero-day biopsy tissue will be stained with Masson's Trichrome staining, Collagen I, III, IV immunostaining to evaluate the degree of fibrosis. Also, by ultracentrifuge, we will extract urinary exosomes and perform proteomics analysis and RNA-sequencing. The association between urinary exosomes and the degree of graft fibrosis will be analyzed to identify biomarkers that represent fibrosis. The correlation between these biomarkers and graft long term outcomes will be investigated.
PURPOSE:To obtain a transparent solid detergent having such a compsn. as to obviate demerits as otherwise involved in production and use thereof. CONSTITUTION:This transparent solid detergent comprises potassium, sodium and ethanolamine salts of an N-long-chain-acylcidic amino acid, and urea blended therewith. The foregoing compsn. can enhance the hardness of the transparent solid detergent to lower the stickiness thereof onto a container therefor particularly in the course of use thereof, and can prevent the detergent from being discolored and changed in the odor thereof during the production and storage at a high. temp..
956,689. Cheese manufacture; making and cutting curd. NEDERLANDS INSTITUUT VOOR ZUIVELONDERZOEK. July 11, 1961 [July 11, 1960], No. 25089/61. Heading A2B. In the manufacture of curd for making cheese a mixture of milk and ingredients required for the production of cheese, e.g. rennet, starter, calcium chloride, saltpetre, colouring, are cooled to and held at a temperature between -1‹C. and +15‹C. in a tank for between 1¢ and 48 hours and then pumped through a heat exchanger, e.g. of plate or tubular type, and heated to a temperature between 20 and 45 ‹C. The mixture then passes into a coagulating chamber having two, preferably horizontal, perforated discs above the inlet with the perforations in staggered relationship to prevent turbulence and proceeds up the chamber to a curd cutting apparatus, Fig. 3. associated with its outlet. As shown, the coagulating chamber comprises concentric cylinders 1, 2 and a knife having a cutting edge 4 and vertical blades 5 is rotated in the annular space between the cylinders. The knife is sector-shaped and the edge 4 is upwardly inclined from B to A, whilst the circular edge BC is inclined upwards in a helix, the arrangement, construction and operation, i.e. speed of rotation, angles of inclination &c., being such that the strips formed by the knives 5 and edge 4 are cut by vertical blades 6 on the outer edge of the cylinder into pieces of curd all of equal volume. Alternative forms of apparatus are described in which the curd is removed from the coagulation chamber either inwardly, i.e. in a direction towards the inner cylinder (Fig. 6, not shown) or alternatively both inwardly and outwardly.
This research project investigates the effects endogenous GIP has in the body of healthy, overweight people. Two trial days will be held. The participant will receive intravenous infusion of either GIP\[3-30\]NH2 (800 pmol/kg/min) or placebo (saline) in a randomized order. After 20 minutes, GIP\[3-30\]NH2 is expected to have maximum effect. On time of 180 minutes, an ad libitum meal is served, which is consumed during continued infusion. When the participant is comfortably full, the infusion is turned off and the trial day ends. During the day, the participant assesses and notes on standardized VAS schedules current appetite, satiety, nausea, fatigue, malaise and thirst. Blood pressure and heart rate are measured every 30 minutes throughout the trial day and blood samples are taken. In total, there will be drawn ten blood samples between intervals of 15 to 30 min. Three times along the way, the activity in the brown adipose tissue is measured with a thermal camera (temperature measurements over the skin on the chest) and the resting metabolic rate is determined with indirect calorimetry (inhaled and exhaled air is captured by breathing under a large plastic bell).
The invention relates to a new Tibetan drug ---"shining pearl" heart-brain through capsule. The drug is made from 9 medicinal materials by using 3 methods of extraction. (1) astragalus root, earth worm, sappan wood and achyranthes root are extracted with water 3 times then the extracted liquids are merged, filtered, concentrated, dried and crushed into powder. (2) chuanxiong rhizome, angelica, gadol are reflux extracted 3 times by 70% alcohol, then merge these extracted liquids, reduced pressure to cover alcohol, concentrated in into paste dried and crushed into powder. (3) arisaema with bile is dried by fire and mixed with saffron, then crushed into powder. Mixing above three powders according to ratio, then adding auxiliary materials to the mixture and packed into capsule. The capsule provides efficiency of promoting blood circulation to dispel blood stasis, soothing the nerves, regulation of qi and the blood, regularizing and balancing the functions of human body. It applies to prevention and cure of coronary sclerosis, coronary heart disease, anemic heart disease, as well as high blood pressure, cerebral thrombosis, sequela of apoplexy. It has features of easy to use, taking effect quickly, high curative ratio and unease recurring. It could relieve thoroughly harassement from high blood pressure and heart disease caused by disease of heart and brain blood vessel.
The invention provides a method for preventing or treating pulmonary edema and/or pulmonary inflammation in a subject by the administration of at least one nucleotidase. The subject is preferably a human subject. The nucleotidase is preferably of a mammalian origin, such as a human origin. The NTPDase and NPP families of nucleotidases are particularly useful for the present invention. The method reduces the bioavailability of in situ signaling extracellular nucleotides, thereby disturbing the pathological pathways in ventilator-induced lung injury (VILI) and respiratory syncytial virus infection (RSV) and other disorders such as chronic obstructive pulmonary disorder. Local administration such as inhalation is a preferred route of administration.
A therapeutic composition comprises 10 parts of hydrocortisone and one part of prednisolane or prednisone.  The active constituents may be used in the form of the free alcohols or as the 21-esters, e.g. acetate, propionate or cyclopentyl propionate or the sodium salt of the 21-hemisuccinate ester.  The compositions are compounded by straight-forward admixture of the active ingredients with a suitable diluent corresponding to the dosage form, i.e. tablets, powders, capsules and liquid suspensions and solutions for oral dosage and suspensions and solutions and dry compositions for subsequent compounding with water for parenteral administration.  Such diluents may be starch, lactose, talc, stearic acid, magnesium stearate, gums, sodium citrate, sodium carboxy methyl cellulose, polyvinyl pyrrolidone and methyl paraben.  Other active medicaments may be incorporated if desired.
Infectious and inflammatory diseases are one of the leading causes of death globally. The status quo has become more prominent with the onset of the coronavirus disease 2019 (COVID-19) pandemic. To combat these potential crises, proteins have been proven as highly efficacious drugs, drug targets, and biomarkers. On the other hand, advancements in nanotechnology have aided efficient and sustained drug delivery due to their nano-dimension-acquired advantages. Combining both strategies together, the protein nanoplatforms are equipped with the advantageous intrinsic properties of proteins as well as nanoformulations, eloquently changing the field of nanomedicine. Proteins can act as carriers, therapeutics, diagnostics, and theranostics in their nanoform as fusion proteins or as composites with other organic/inorganic materials. Protein-based nanoplatforms have been extensively explored to target the major infectious and inflammatory diseases of clinical concern. The current review comprehensively deliberated proteins as nanocarriers for drugs and nanotherapeutics for inflammatory and infectious agents, with special emphasis on cancer and viral diseases. A plethora of proteins from diverse organisms have aided in the synthesis of protein-based nanoformulations. The current study specifically presented the proteins of human and pathogenic origin to dwell upon the field of protein nanotechnology, emphasizing their pharmacological advantages. Further, the successful clinical translation and current bottlenecks of the protein-based nanoformulations associated with the infection-inflammation paradigm have also been discussed comprehensively. SIGNIFICANCE STATEMENT: This review discusses the plethora of promising protein-based nanocarriers and nanotherapeutics explored for infectious and inflammatory ailments, with particular emphasis on protein nanoparticles of human and pathogenic origin with reference to the advantages, ADME (absorption, distribution, metabolism, and excretion parameters), and current bottlenecks in development of protein-based nanotherapeutic interventions.
PURPOSE: Orbital implant exposures, infections, and extrusions can occur many years following enucleation or evisceration. This study analyzes complication rates following porous orbital implant wrapped with a posterior auricular muscle complex graft (PAMCG).
METHODS: This is a retrospective study of patients who underwent orbital implantation following enucleation using this technique between 1992 and 2013. Only cases with a minimum of 18 months of follow-up were included. No patients underwent peg implantation. Patient's demographics, follow-up time, type of implant, complications including wound dehiscence, exposure, postoperative infection, and extrusion were recorded.
RESULTS: This study included 36 orbits of 36 patients with a mean age of 39.3 ± 23.2 years (range, 3-84 years). Thirty patients had hydroxyapatite implants and six had porous polyethylene. The average follow-up time was 12.6 ± 5.6 years (range, 1.5-31.0 years). There were no implant extrusions, and only one exposure resulting in orbital infection that necessitated implant removal (2.8%).
CONCLUSION: Wrapping porous orbital implants with PAMCG had favorable long-term outcomes over a thirty-one-year period.
RAD001 given 10mg/daily by mouth and 400mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
Bacterial Vaginosis (BV), defined as an alteration in the normal vaginal bacteria ("microbiome"), is characterized by a reduction of hydrogen peroxide-producing gram-positive lactobacilli and overgrowth of gram-negative and anaerobic bacteria. BV is more prevalent in SSA and usually recurs soon after treatment. BV is associated with vaginal inflammation, an increased HIV acquisition risk among uninfected women, and increased HIV transmission to the male sexual partner of a co-infected woman. Therefore, BV may be responsible for up to 17% of HIV transmission events in SSA.

There are several hypotheses for the mechanisms by which BV may increase the risk of HIV acquisition. These include the disruption of mucosal barrier, alteration of protective innate immunity, and increased number and/or susceptibility of HIV target cells in the genital mucosa. Longitudinal studies that address the mechanisms by which the vaginal microbiota alters host mucosal immunology and HIV risk will help us better understand the impact of BV and it's treatment on mucosal immunology and HIV susceptibility. The goal of this non-randomized, interventional, longitudinal clinical study is to use a novel ex vivo HIV infectivity assay developed in the Kaul lab to quantify the effect of BV and its treatment on HIV susceptibility and genital immunology in HIV-uninfected women from Nairobi, Kenya. Fifty HIV, STI-uninfected women with bacterial vaginosis on Nugent scoring will be provided with one week of metronidazole 400mg po three times daily (as per Kenyan National Guidelines). Cytobrush and vaginal SoftCup sampling will be performed at baseline and 4 weeks after treatment initiation, at the same stage of the menstrual cycle. The primary endpoint will be pseudovirus entry into cervix-derived CD4+ T cells. Secondary endpoints will include a pre-defined cervico-vaginal inflammation score; genital CD4+ T cell immune characteristics; the genital microbiome; the genital proteome.
It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
INTRODUCTION: Gastric bypass has not gained as much popularity in the Czech Republic as technically simpler restrictive bariatric procedures, frequently with a fading long-term effect. The aim of the presentation is to point out the long-term results after two types of gastric bypasses.
METHOD: Retrospective analysis of prospectively collected data in an initial set of patients after laparoscopic RYGB (Roux Y gastric bypass) and OAGB/MGB (one anastomosis/mini gastric bypass) performed at Breclav Hospital in 2010-2013. Evaluation based on the BAROS system, according to weight development, comorbidities, psychological aspects, complications and reoperations.
RESULTS: Data available for evaluation are from 32 patients out of a total of 60; the follow-up rate is 53%. The patients are lighter by 34 kg on average (0-64 kg); TBWL (total basic weight loss): 25.7%. The majority of operated diabetics are free of signs of diabetes, and all others have a reduced need for antidiabetic medication. Hypertension, sleep apnea and psychological assessment of life in 6 domains improved. Eight of the 32 followed patients underwent reoperation during 10 years; only 2 of these procedures were acute for complications (anastomotic ulceration), both in smokers; further elective reoperations included 2 conversions of OAGB/MGB to RYGB due to reflux, 2 corrective surgeries, and 2 procedures for a suspected internal hernia. There was no conversion from laparoscopic to open surgery, no peritonitis associated with a leak, and no mortality within 30 days. The BAROS score (5.56) indicates a "very good result" of the gastric bypasses after 10 years.
CONCLUSION: Gastric bypasses are safe and provide a high and lasting metabolic effect that meets the general expectations of an invasive intervention that can fundamentally improve the quality of treatment for otherwise incurable chronic diseases related to adiposity (so-called ABCD), especially type 2 diabetes.
IgA vasculitis nephritis (IgAVN), a type of immune system disease characterized by the deposition of IgA in the mesangial area of the glomerulus, is most common in children. Corticosteroids and immunosuppressants agents are commonly prescribed for the clinical management of IgAVN; however, these therapies are associated with numerous adverse reactions. This necessitates the discovery of alternative, potential therapeutic agents that can offer a safer treatment option. Natural plants contain abundant total glucosides of paeony (TGP), which represent one of the most prevalent secondary metabolites found within these organisms. TGP has been proven to be a safe and desirable natural medicine, with the most central ingredient being polyphenolic. TGP, a naturally occurring and cost-effective compound, exerts its therapeutic influence on IgAVN via diverse pathways and targets, with minimal side effects. Its substantial clinical potential underscores the importance of delving deeper into its pharmacological mechanisms, which hold great promise for novel drug development. This review examines the multifaceted therapeutic mechanisms of TGP in IgAVN encompassing modulation of Wnt/β-catenin pathways and programmed cell death pathways, antioxidant and anti-inflammatory effects, and enhancement of vascular repair. Additionally, we provide an overview of recent advancements in enhancing the bioavailability of TGP and highlight crucial considerations that may inform future research endeavors.
The invention discloses a composition with sleep-aiding efficacy, a spray and a preparation method thereof. The composition with the sleep-aiding efficacy comprises the following components in percentage by mass: sandalwood oil: butter oil: bitter orange flower oil: the rosewood oil is 2-4: 1-2: 1-2: 1 to 2. Meanwhile, the invention also provides a sleep-aiding spray containing the composition. According to the invention, by strictly selecting the matching and adding proportion of the perfume components, the perfume components are matched with the hemp leaf extract to cooperatively play a sleep-aiding effect, the smell is relaxed, and the sleep-aiding effect is obvious. The active substances in the spray are all selected from natural plants, do not contain harmful substances, have no side effect, are natural and safe, and can be used for a long time. Meanwhile, when the sleep-aiding spray is used, the fragrance is released more quickly and mildly, and the fragrance is released more comprehensively. The product of the invention has simple preparation process, controllable proportion of the aroma components and low cost, and is suitable for industrial production.
PURPOSE: A composition containing Piper retrofractum Vahl extract is provided to reduce body fat and body weight and to prevent and treat obesity. CONSTITUTION: A functional composition for anti-obesity contains Piper retrofractum Vahl fruit extract an active ingredient and reduces body weight and body fat. The extract is prepared from Piper retrofractum Vahl fruit powder using an organic solvent or by supercritical extraction. A functional food or pharmaceutical composition for anti-obesity contains the extract as an active ingredient. The composition contains 0.001-80 wt% of the extract. [Reference numerals] (AA) Body weight; (BB) Mouse weight(g); (CC) Weeks
Diabetes mellitus (DM) is a pervasive global health issue with substantial morbidity and mortality, often resulting in secondary complications, including diabetic wounds (DWs). These wounds, arising from hyperglycemia, diabetic neuropathy, anemia, and ischemia, afflict approximately 15% of diabetic patients, with a considerable 25% at risk of lower limb amputations. The conventional approaches for chronic and diabetic wounds management involves utilizing various therapeutic substances and techniques, encompassing growth factors, skin substitutes and wound dressings. In parallel, emerging cell therapy approaches, notably involving adipose tissue-derived mesenchymal stem cells (ADMSCs), have demonstrated significant promise in addressing diabetes mellitus and its complications. ADMSCs play a pivotal role in wound repair, and their derived exosomes have garnered attention for their therapeutic potential. This review aimed to unravel the potential mechanisms and provide an updated overview of the role of ADMSCs and their exosomes in diabetes mellitus and its associated complications, with a specific focus on wound healing.
This is a prospective, multicenter center, open-label, randomized trial to compare QCA-guided versus FFR-guided CR strategies in patients with significant CAD who are undergoing PCI with DES. Patients with symptoms or evidence of myocardial ischemia are eligible for enrollment if there have stenotic lesions with a diameter stenosis of 50%-90% in major epicardial coronary arteries ≥ 2.25 mm in diameter by visual estimation, and CR is expected to be achievable by PCI. The detailed information for inclusion and exclusion criteria is described below in the session 4. Patients meeting inclusion criteria without any exclusion criteria will be randomized to either QCA-guided CR or FFR-guided CR group. In the QCA-guided CR group, PCI will be performed if there are lesions with diameter stenosis ≥ 50% by QCA during the index procedure (and, if necessary, planned staged procedure). In the FFR-guided CR group, FFR is measured for the target coronary lesions, and then PCI will be performed for the lesions with FFR ≤0.80. Post-PCI FFR measurement is strongly recommended. However, additional procedures are not recommended based on post-PCI FFR value because there is no consensus of the optimal cut-off value to define physiologic CR. In both QCA-guided and FFR-guided PCI groups, imaging guidance during PCI is left at the discretion of the operator. However, routine high pressure post-dilation with noncompliant balloons is recommended to achieve optimal stent expansion with minimal residual stenosis (diameter stenosis \< 10% on visual estimation). Patients will be followed clinically at 1, 6, 12 months, and then upto 5 years after the index procedure
Gap junctions (GJs) are important in the regulation of cell growth, morphology, differentiation and migration. However, recently, more attention has been paid to their role in the pathogenesis of different diseases as well as tumorigenesis, invasion and metastases. The expression pattern and possible role of connexins (Cxs), as major GJ proteins, under both physiological and pathological conditions in the adrenal gland, were evaluated in this review. The databases Web of Science, PubMed and Scopus were searched. Studies were evaluated if they provided data regarding the connexin expression pattern in the adrenal gland, despite current knowledge of this topic not being widely investigated. Connexin expression in the adrenal gland differs according to different parts of the gland and depends on ACTH release. Cx43 is the most studied connexin expressed in the adrenal gland cortex. In addition, Cx26, Cx32 and Cx50 were also investigated in the human adrenal gland. Cx50 as the most widespread connexin, along with Cx26, Cx29, Cx32, Cx36 and Cx43, has been expressed in the adrenal medulla with distinct cellular distribution. Considerable effort has recently been directed toward connexins as therapeutically targeted molecules. At present, there exist several viable strategies in the development of potential connexin-based therapeutics. The differential and hormone-dependent distribution of gap junctions within adrenal glands, the relatively large gap junction within this gland and the increase in the gap junction size and number following hormonal treatment would indicate that gap junctions play a pivotal role in cell functioning in the adrenal gland.